DK1240901T3 - Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation - Google Patents

Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation

Info

Publication number
DK1240901T3
DK1240901T3 DK00987688T DK00987688T DK1240901T3 DK 1240901 T3 DK1240901 T3 DK 1240901T3 DK 00987688 T DK00987688 T DK 00987688T DK 00987688 T DK00987688 T DK 00987688T DK 1240901 T3 DK1240901 T3 DK 1240901T3
Authority
DK
Denmark
Prior art keywords
blood coagulation
prevention
treatment
disorders
pharmaceutical composition
Prior art date
Application number
DK00987688T
Other languages
English (en)
Inventor
Tatsuya Araki
Yasushi Nakatomi
Kazuhiko Tomokiyo
Kaori Teshima
Tomoko Watanabe
Tomohiro Nakagaki
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of DK1240901T3 publication Critical patent/DK1240901T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK00987688T 1999-12-24 2000-12-21 Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation DK1240901T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP36812299A JP4676585B2 (ja) 1999-12-24 1999-12-24 血液凝固異常に基づく疾患の治療・予防用医薬組成物
PCT/JP2000/009102 WO2001047548A1 (fr) 1999-12-24 2000-12-21 Compositions medicinales de traitement et de prevention de maladies basees sur une coagulation sanguine anormale

Publications (1)

Publication Number Publication Date
DK1240901T3 true DK1240901T3 (da) 2008-11-10

Family

ID=18491024

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00987688T DK1240901T3 (da) 1999-12-24 2000-12-21 Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation

Country Status (9)

Country Link
US (1) US6881721B2 (da)
EP (1) EP1240901B1 (da)
JP (1) JP4676585B2 (da)
CN (1) CN1222311C (da)
AT (1) ATE407692T1 (da)
DE (1) DE60040236D1 (da)
DK (1) DK1240901T3 (da)
ES (1) ES2312374T3 (da)
WO (1) WO2001047548A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4813017B2 (ja) 2001-07-10 2011-11-09 一般財団法人化学及血清療法研究所 薬剤学的に安定な止血用組成物
JP2007055899A (ja) * 2003-10-27 2007-03-08 Chemo Sero Therapeut Res Inst 血液凝固第ｘ因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2008023052A1 (en) * 2006-08-24 2008-02-28 Novo Nordisk Health Care Ag Combination of a fvii and a thrombin-activable factor x
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
DK2555704T3 (da) 2010-04-08 2019-08-05 Hemosonics Llc Visning af hæmostatiske parametre

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287180A (en) 1980-01-28 1981-09-01 Baxter Travenol Laboratories, Inc. Method for treating blood clotting factor inhibitors
US4663164A (en) 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
US4357321A (en) * 1980-01-28 1982-11-02 Baxter Travenol Laboratories, Inc. Method and composition for treating clotting factor inhibitors
US4286056A (en) 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
EP0044343B1 (en) 1980-01-28 1984-08-22 Baxter Travenol Laboratories, Inc. Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions
US4459288A (en) * 1981-05-11 1984-07-10 Baxter Travenol Laboratories, Inc. Therapeutic blood clotting factor compositions and their use
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
ATE200225T1 (de) * 1994-04-22 2001-04-15 Sanquin Bloedvoorziening Mittel für die behandlung von störungen des blutgerinnungsprozess
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
JP4046377B2 (ja) 1996-08-19 2008-02-13 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子の活性化方法及び該方法に基づく活性化血液凝固第ｖｉｉ因子の製造方法
JPH1059866A (ja) 1996-08-19 1998-03-03 Chemo Sero Therapeut Res Inst 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法

Also Published As

Publication number Publication date
ES2312374T3 (es) 2009-03-01
CN1434720A (zh) 2003-08-06
JP4676585B2 (ja) 2011-04-27
EP1240901B1 (en) 2008-09-10
WO2001047548A1 (fr) 2001-07-05
JP2001181204A (ja) 2001-07-03
EP1240901A1 (en) 2002-09-18
DE60040236D1 (de) 2008-10-23
ATE407692T1 (de) 2008-09-15
EP1240901A4 (en) 2005-01-12
US6881721B2 (en) 2005-04-19
US20030060411A1 (en) 2003-03-27
CN1222311C (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
Bidolegui et al. Tranexamic acid reduces blood loss and transfusion in patients undergoing total knee arthroplasty without tourniquet: a prospective randomized controlled trial
Ramström et al. Prevention of postsurgical bleeding in oral surgery using tranexamic acid without dose modification of oral anticoagulants
Honickel et al. Prothrombin complex concentrate is effective in treating the anticoagulant effects of dabigatran in a porcine polytrauma model
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
MY125150A (en) Factor vlla inhibitors
Notarnicola et al. Comparative efficacy of different doses of fibrin sealant to reduce bleeding after total knee arthroplasty
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
Liu et al. Tranexamic acid reduces occult blood loss, blood transfusion, and improves recovery of knee function after total knee arthroplasty: a comparative study
Pachauri et al. The effect of tranexamic acid on hemoglobin levels during total knee arthroplasty
WO2007106893A3 (en) Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors
DE50010284D1 (de) Arzneimittel zur behandlung von bluthochdruck
DK1240901T3 (da) Medicinske præparater til behandling og forebyggelse af sygdomme baseret på abnorm blodkoagulation
DE69934689D1 (de) Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen
Bernet et al. Reduction of blood loss and transfusion requirements after coronary artery bypass grafting: similar efficacy of tranexamic acid and aprotinin in aspirin‐treated patients
Petratos et al. Transforming growth factor‐β2 (TGF‐β2) reverses the inhibitory effects of fibrin sealant on cutaneous wound repair in the pig
FR2773712B1 (fr) Composition pharmaceutique comprenant au moins un inhibiteur de l'aminopeptidase a
GB9930768D0 (en) Composition
NO20021410D0 (no) Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
Franchini et al. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
ATE337790T1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
Krishnan et al. Effects Of Haemostatic Agents On Bond Strength–An In Vitro Study
ATE439142T1 (de) Kombination von aktiviertem factor viia und fibrinogen und verwendung zur behandlung von blutung
ATE320817T1 (de) Antiglaukomatoses mittel und dessen verwendung